GLP-1 drugs reduce cancer risks for diabetes patients

A study reveals that diabetes patients on GLP-1 drugs, like Ozempic, have lower risks of 10 obesity-related cancers. GLP-1 therapies, including Ozempic and Mounjaro, have shown significant benefits for blood sugar control and weight loss. The study, analyzing 1.6 million patients, was published on July 5, 2024, in JAMA Network Open. Novo Nordisk and Eli Lilly are experiencing increased profits due to the popularity of these treatments.